Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound
- PMID: 33972578
- PMCID: PMC8110815
- DOI: 10.1038/s41598-021-89128-0
Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound
Abstract
The anticancer activity of bortezomib (BTZ) has been increasingly studied in a number of indications and promising results for the use of this treatment have been shown in neuroblastoma. As BTZ treatment is usually administered in cycles, the development of resistance and side effects in patients undergoing therapy with BTZ remains a major challenge for the clinical usage of this compound. Common resistance development also means that certain cells are able to survive BTZ treatment and bypass molecular mechanisms that render BTZ anticancer activity. We studied the methylome of neuroblastoma cells that survived BTZ treatment. Our results indicate that BTZ induces pronounced genome wide methylation changes in cells which recovered from the treatment. Functional analyses of identified methylation changes demonstrated they were involved in key cancer pathology pathways. These changes may allow the cells to bypass the primary anticancer activity of BTZ and develop a treatment resistant and proliferative phenotype. To study whether cells surviving BTZ treatment acquire a proliferative phenotype, we repeatedly treated cells which recovered from the first round of BTZ treatment. The repetitive treatment led to induction of the extraordinary proliferative potential of the cells, that increased with subsequent treatments. As we did not observe similar effects in cells that survived treatment with lenalidomide, and non-treated cells cultured under the same experimental conditions, this phenomenon seems to be BTZ specific. Overall, our results indicate that methylation changes may play major role in the development of BTZ resistance.
Conflict of interest statement
The authors declare no competing interests.
Figures






Similar articles
-
5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.Int J Mol Sci. 2023 Nov 26;24(23):16780. doi: 10.3390/ijms242316780. Int J Mol Sci. 2023. PMID: 38069103 Free PMC article.
-
Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib.PLoS One. 2016 Mar 29;11(3):e0152465. doi: 10.1371/journal.pone.0152465. eCollection 2016. PLoS One. 2016. PMID: 27023064 Free PMC article.
-
HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.Biochim Biophys Acta. 2014 Apr;1842(4):613-22. doi: 10.1016/j.bbadis.2013.12.008. Epub 2013 Dec 28. Biochim Biophys Acta. 2014. PMID: 24380881
-
Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.Adv Cancer Res. 2015;127:191-226. doi: 10.1016/bs.acr.2015.03.002. Epub 2015 Apr 11. Adv Cancer Res. 2015. PMID: 26093901 Review.
-
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Expert Opin Drug Discov. 2017 Feb;12(2):225-235. doi: 10.1080/17460441.2017.1268596. Epub 2016 Dec 20. Expert Opin Drug Discov. 2017. PMID: 27917682 Free PMC article. Review.
Cited by
-
Long-Term Treatment with Bortezomib Induces Specific Methylation Changes in Differentiated Neuronal Cells.Cancers (Basel). 2022 Jul 13;14(14):3402. doi: 10.3390/cancers14143402. Cancers (Basel). 2022. PMID: 35884461 Free PMC article.
-
Potential Benefits of Dietary Plant Compounds on Normal and Tumor Brain Cells in Humans: In Silico and In Vitro Approaches.Int J Mol Sci. 2023 Apr 17;24(8):7404. doi: 10.3390/ijms24087404. Int J Mol Sci. 2023. PMID: 37108565 Free PMC article.
-
Ubiquitin proteasome system (UPS): a crucial determinant of the epigenetic landscape in cancer.Epigenomics. 2025 Jun;17(9):625-644. doi: 10.1080/17501911.2025.2501524. Epub 2025 May 8. Epigenomics. 2025. PMID: 40337853 Review.
-
Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action.Cancers (Basel). 2023 Dec 23;16(1):84. doi: 10.3390/cancers16010084. Cancers (Basel). 2023. PMID: 38201512 Free PMC article. Review.
-
Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications.EXCLI J. 2023 Jan 16;22:146-168. doi: 10.17179/excli2022-5653. eCollection 2023. EXCLI J. 2023. PMID: 36998701 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials